Figure 4
Evaluation of the antiviral efficacy of the neutralizing antibodies in vivo using the bioluminescence imaging of rTV-Fluc.
(a) Bioluminescence imaging of Rag2-/- and SD rats. At 35d post initial inoculation, rats infected with rTV-Fluc via ID or IV inoculation were reinfected with 5 × 106 p.f.u rTV-Fluc by ID injection and naive rats were inoculated with PBS as controls. A representative animal from each group was shown. (b) The vaccinia virus neutralizing antibody titers were determined in Rag2-/- and SD rats at 35d post initial infection. Each data column represents mean ± SEM (n = 6). (c) Correlation of total flux peak in SD rats at 1d post initial infection to neutralizing antibody titers detected at 35 days later. (d) Values of total flux for Rag2-/- and SD rats at 1d after reinfection and naive SD rats as controls. The statistical significance was calculated using ANOVA. (e) Correlation of the neutralizing antibody titers with the inhibition percentage of bioluminescent intensity at day 1 post reinfection.
